Eidos Therapeutics, a subsidiary of BridgeBio Pharma, is developing AG10 as a targeted therapeutic for transthyretin amyloidosis. The company’s singular mission is to improve and prolong the lives of patients suffering from this disease.

Launched in 2016 after years of research supported by Stanford’s SPARK program, Eidos is led by a team of veteran biotechnology executives. Together with patients and physicians, the company aims to bring a safe, effective treatment to market as quickly as possible.

Biotechnology

Eidos Therapeutics

Eidos Therapeutics' headquarters in San Francisco, CA, United States

Neil Kumar

Uma Sinha

Matt Outten

Mamoun Alhamadsheh

Isabella Graef

The Clinical Research and Development team at Eidos Therapeutics is dedicated to designing, implementing, and overseeing clinical trials aimed at evaluating the safety and efficacy of AG10 for transthyretin amyloidosis. This team, composed of experienced professionals in clinical operations and regulatory affairs, collaborates closely to ensure trials meet regulatory standards and are conducted efficiently, ultimately working to bring innovative therapies to patients in need.

Clinical Research and Development

The Leadership Team at Eidos Therapeutics is responsible for guiding the strategic direction and operational execution of the company. Comprising seasoned biotechnology executives and co-founders, this team collaborates to drive the development of AG10, ensuring alignment with the company’s mission to improve the lives of patients with transthyretin amyloidosis. They focus on making critical decisions regarding research priorities, commercial strategy, and partnership opportunities to expedite the delivery of safe and effective therapies to market.

Leadership Team

The Research and Development team at Eidos Therapeutics is responsible for advancing the scientific discovery and clinical development of AG10, a targeted therapy for transthyretin amyloidosis. Comprising experts in various scientific and clinical fields, the team conducts rigorous research, designs and executes preclinical and clinical trials, and collaborates closely with regulatory bodies to ensure the safe and effective progression of the therapeutic from concept to market. Their work is essential in fulfilling the company’s mission to improve the lives of patients affected by this condition.

Research and Development

The Quality Assurance and Compliance team at Eidos Therapeutics is responsible for ensuring that all processes, procedures, and products meet regulatory standards and internal quality benchmarks. They oversee the implementation of quality management systems, maintain compliance with FDA regulations, and manage documentation control to support the development of AG10. Their mission is to uphold the highest standards of safety and efficacy for patients, facilitating the timely and successful introduction of innovative therapeutics to the market.

��

Eidos Therapeutics

Org chart

Board & advisors

Teams

Clinical Research and Development

Leadership Team

Research and Development

Quality Assurance and Compliance

Offices

��������

Eidos Therapeutics

Org chart

Board & advisors

Teams

Clinical Research and Development

Leadership Team

Research and Development

Quality Assurance and Compliance

Offices

Related companies

��